Literature DB >> 22493368

The value of induction chemotherapy for survival in patients with non-small cell lung cancer treated with radiotherapy.

Georg Holgersson1, Martin Sandelin, Even Hoye, Stefan Bergström, Roger Henriksson, Simon Ekman, Jan Nyman, Martin Helsing, Signe Friesland, Ola Brodin, Margareta Holgersson, Kristina Lamberg Lundström, Christer Janson, Lars Ekberg, Charlotte Mörth, Thomas Blystad, Sven-Börje Ewers, Britta Löden, Michael Bergqvist.   

Abstract

AIM: The aim of the present study was to retrospectively investigate the impact of induction chemotherapy on treatment outcome in patients treated with curatively intended radiotherapy for non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients with a diagnosed NSCLC that have been subjected to curatively intended irradiation (≥50 Gy) and treated in an oncology department in Sweden during the years 1990-2000 were included in the study. Operated patients and patients having received concomitant chemotherapy were excluded. The included patients were localised by a manual search of all the oncology departments' medical records and radiation charts.
RESULTS: Patients treated with induction chemotherapy (n=79) had a significantly better overall survival compared with patients treated with radiotherapy alone (p=0.0097) in a univariate Cox regression analysis. A platinum/taxane combination produced the greatest survival benefit; hazard ratio=0.49 (95% confidence interval=0.31 to 0.75).
CONCLUSION: We found that patients treated with induction chemotherapy in addition to radiotherapy for NSCLC have a better overall survival than patients treated with radiotherapy alone and that the best results are achieved using a platinum/taxane combination.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22493368

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  Chemoradiotherapy versus radiotherapy alone following induction chemotherapy for elderly patients with stage III lung cancer.

Authors:  Dong-Yun Kim; Changhoon Song; Se Hyun Kim; Yu Jung Kim; Jong Seok Lee; Jae-Sung Kim
Journal:  Radiat Oncol J       Date:  2019-09-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.